Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (CDF review TA528): Appraisal consultation document

DRAFT NICE guidance recommends niraparib as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults, only if they meet stated criteria & it is provided according to the commercial arrangement

SPS commentary:

The DRAFT guidance recommends use of niraparib in this setting only in individuals who have a BRCA mutation and have had 2 courses of platinum-based chemotherapy and their disease has responded to the most recent one.

National Institute for Health and Care Excellence